Progyny, Inc.

Valuation Analysis

About the Company

Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimburse

Progyny, Inc. Stock at a Glance

Progyny, Inc. (PGNY) is currently trading at $26.63 with a market capitalization of $2.1B. The trailing P/E ratio stands at 34.58x, with a forward P/E of 12.07x. The 52-week range spans from $16.10 to $28.75; the current price is 7.4% below the yearly high. Year-over-year revenue growth stands at +1.4%. The net profit margin stands at 5.24%.

💰 Dividend

Progyny, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

11 analysts rate Progyny, Inc. (PGNY) on consensus: Strong Buy. The average price target is $29.73, implying +11.63% from the current price. Analyst price targets range from $26.00 to $31.00.

Progyny, Inc.: The Investment Case in Detail

Progyny, Inc. (PGNY) operates in the Healthcare — specifically Healthcare Plans — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 70.6% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base.

The Bear Case

Revenue growth has slowed to just 1.4%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

What to Watch Next

• The forward P/E of 12.07x is meaningfully below the trailing 34.58x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (9.09%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Progyny, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.